Comparison of the Efficacy of Different First-Line Therapies for EGFR L858R-Mutated NSCLC Patients With Brain Metastases. Chen J, Pan Y, Zhang B, Li M, et al. Cancer Sci 2025;116:3125-3138.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Chen J, Pan Y, Zhang B, Li M, et al. Comparison of the Efficacy of Different First-Line Therapies for EGFR L858R-Mutated NSCLC Patients With Brain Metastases. Cancer Sci 2025;116:3125-3138.
PMID: 40817635